Alison Kanski

Researchers explored whether the uptake of pre-test education and cancer risk genetic testing was similar for patients who used a chatbot or met with a genetic counselor.

The agency is considering whether to limit the indications of Keytruda, Opdivo, and Tevimbra to PD-L1-positive patients amid testing uncertainties. 

The ODAC will weigh risk-benefit analyses from the FDA and sponsors on Keytruda, Opdivo, and Tevimbra when given with chemo in all-comers and in PD-L1-positive subgroups.

Researchers reported at the ESMO Congress that 78 percent of patients responded to front-line treatment with Lumakras, Vectibix, and chemo.

Researchers explored HER2 testing discordance, biomarkers of response, patient-reported outcomes, and the risk of lung-related disease.

Experts noted, however, there is insufficient evidence to determine which commercially available KRAS G12C inhibitor is the best treatment for brain metastases.

The results, published in Nature Medicine, strengthen oncologists' understanding of Enhertu's clinical activity as a second-line option for metastatic breast cancer, experts said.

The Phase II results bolster the firm's confidence in the c-MET expression cutoff it has established in an ongoing Phase III trial of the drug.

In the TRUST-II trial, 85 percent of ROS1 TKI-naïve NSCLC patients and 62 percent of TKI-pretreated patients responded to the next-generation ROS1 inhibitor.

As demand for virtual MTBs grow, the challenge now is to manage treating oncologists' time so they can better engage with MTBs and MTBs can review more cases.